AGP Executive Report

Cardiac Care Spotlight: Denmark’s Christian Eriksen is back home and “doing well” after collapsing again during the Denmark–Ukraine friendly in Odense; the match was abandoned, he was briefly unconscious, and his implantable cardioverter-defibrillator (ICD) reportedly did what it was designed to do, with team doctor Morten Boesen saying he’s expected to be discharged soon and recovery has started. Sports Medicine & Mental Health: The Danish FA moved quickly to support shocked players and staff, including plans to avoid anyone travelling home alone after the on-pitch emergency. School Health Policy: Sweden is set to ban mobile phones in schools from next fall, citing falling reading and writing skills and a broader push to reduce screen time—Denmark is expected to follow similar steps. HIV Treatment Research: A new study suggests most “nonsuppressible” HIV traces during long-term ART come from defective, noninfectious viral copies, offering reassurance to patients worried about viral rebound. Obesity Drugs Watch: AstraZeneca reported promising phase 2 results for an oral weight-loss pill (elecoglipron), with weight reductions comparable to other oral GLP-1 options.

Cardiac Safety Update: Denmark’s Christian Eriksen collapsed again during the 65th minute of the Denmark–Ukraine friendly in Odense, prompting the match to be abandoned; the Denmark team doctor says he is “doing well,” in good spirits with family, and expected to be discharged soon, with Eriksen stressing the incident was different from his 2021 cardiac arrest because his ICD “did exactly what it was designed to do.” Public Health & Prevention: A new genomic test co-developed in Canada is reported to help many breast cancer patients safely avoid chemotherapy, using tumour gene activity to guide treatment decisions. Health Policy & Youth Risk: Denmark is mentioned among countries moving to restrict flavoured nicotine products as WHO-backed efforts gain momentum, with health groups warning sweet flavours can make vaping more appealing to minors. Biotech Watch: Zealand Pharma reported share buy-back and employee-warrant-driven share capital changes, while broader obesity-drug competition continues to heat up.

Sports Medicine Update: Christian Eriksen collapsed again during Denmark’s friendly vs Ukraine in Odense, clutching his chest in the 65th minute; Denmark’s team doctor Morten Boesen says Eriksen was briefly unconscious but regained consciousness quickly, walked off the pitch himself, and his implanted device “responded as it should,” with further hospital tests planned and the match abandoned. Public Health Research: A Danish-led study linking nitrate source to dementia risk reports higher nitrate from vegetables is associated with lower dementia risk, while nitrate/nitrite from animal products, processed meats, and drinking water correlates with higher risk—adding fuel to debates on diet and water quality. Obesity Drug Watch: Novo Nordisk presented Phase 3 REIMAGINE results for CagriSema (once-weekly) showing significant HbA1c and weight reductions in type 2 diabetes, alongside broader cardiometabolic interest in next-gen GLP-1/related therapies. Policy & Prevention: Denmark is among countries restricting flavoured nicotine products, as WHO calls for broader bans to curb youth addiction and related respiratory and cardiovascular harms.

Sports Medicine Update: Denmark’s football federation says Christian Eriksen is conscious and “doing well under the circumstances” after collapsing again during the friendly vs Ukraine in Odense, with the match abandoned; team doctor Morten Boesen reports the implanted defibrillator/pacemaker responded as it should, though Eriksen will undergo further hospital tests to find the cause. Obesity Drug Watch: Zealand Pharma-backed survodutide (licensed to Boehringer Ingelheim) showed targeted reductions in visceral fat (up to 34%) and liver fat (up to 63%) with limited lean-mass loss in late-stage analysis, adding momentum to the next wave of obesity treatments. Patient Support in Focus: At EULAR 2026, the Danish Rheumatism Association highlighted a multidisciplinary counselling service for people with rheumatic diseases, offering person-centred support via a 27-hour weekly phone line and written responses. Local Health Community: EULAR also spotlighted how patient organizations can strengthen access to practical guidance beyond clinical appointments, including employment and physiotherapy concerns. Early-Stage Pipeline: Antag Therapeutics presented first-in-human Phase 1 data for AT7687, a once-weekly GIP receptor antagonist peptide, reporting good tolerability and plans for a Phase 2a start mid-2026.

Obesity & Sleep Apnea Breakthrough: Eli Lilly’s next-gen obesity drug retatrutide cut moderate-to-severe obstructive sleep apnea severity by 60.6% in a Phase 3 trial, while also reducing knee osteoarthritis pain and supporting major weight loss—presented at the American Diabetes Association conference. Danish Obesity Pipeline: Novo Nordisk shared new ADA data on semaglutide, including post-hoc findings tied to obstructive sleep apnea and other obesity-related conditions, as the race to expand anti-obesity indications heats up. Diabetes Drug Update (Denmark-linked): Zealand Pharma and Roche presented tolerability-focused midphase results for petrelintide, highlighting mostly mild GI side effects and a tolerability edge in the ZUPREME-1 trial. Diabetes + Weight Loss Candidate: Novo Nordisk also reported Phase 2 zenagamtide results in type 2 diabetes, with up to 14.6% weight loss and strong A1C reductions, moving the once-weekly candidate toward Phase 3. Cancer Care Warning: A new study in Lancet Oncology says pandemic-era diagnostic gaps led to more than 55,000 expected missed cancer diagnoses across seven countries (including Denmark), raising fears of later-stage disease and worse outcomes. Dog Welfare & Ethics: University of Copenhagen research links dog owners’ training choices to their ethical views, with welfare-oriented owners less likely to use punishment-based methods.

Obesity Drug Pipeline: Novo Nordisk’s investigational zenagamtide posted phase 2b results in type 2 diabetes, with up to 14.6% average weight loss at week 36 and HbA1c reductions up to 1.7%, plus most A1c targets under 7%—setting up phase 3. Diabetes & Weight-Loss Competition: Zealand Pharma reported encouraging tolerability for petrelintide in a mid-stage trial, with low treatment discontinuation (1.5%) and mostly mild GI side effects, while also improving cardiovascular risk markers—positioning it as a potentially gentler option. Rheumatology Setback: Low-dose naltrexone failed to beat placebo for fibromyalgia pain or key secondary outcomes in a well-designed EULAR trial, though participants who believed they were on treatment reported some symptom improvements. Public Health Watch: STI rates in Ireland fell year-on-year in 2025, but remain well above pre-pandemic levels, with gonorrhoea and chlamydia still driving most cases. Denmark Angle: A Danish-linked academic freedom case at the University of Copenhagen faces criminal prosecution over protests, raising concerns about how dissent is handled.

Obesity Drug Watch (Denmark): Zealand Pharma reported new Phase 2 ZUPREME-1 data for petrelintide at the ADA meeting, showing clinically meaningful, double-digit weight loss by week 42 with low treatment discontinuation from gastrointestinal side effects, plus improvements in cardiometabolic risk markers—pushing plans for Phase 3 later in 2026. Diabetes & Genetics: A new study suggests about 10% of people carry genetic variants linked to “GLP-1 resistance,” potentially reducing how well GLP-1 drugs control blood sugar for some patients, raising questions about who benefits most. Migraine Pipeline (Denmark): Lundbeck’s bocunebart migraine prevention trial showed a stronger reduction in monthly migraine days versus placebo at 12 weeks, with generally tolerable side effects, supporting further development. Healthcare Innovation (AI): OpenAI updated GPT-Rosalind for life sciences research, expanding capabilities for drug discovery and lab troubleshooting via a wider trusted-access rollout. Mental Wellbeing for Expats: A Danish counsellor highlights how internationals can experience emotional exhaustion abroad and are increasingly using AI tools as “shadow therapists,” raising both promise and ethics concerns. Public Health Policy (Tobacco): A letter urges Ireland to adopt a generational ban on tobacco sales, arguing harm reduction is no longer enough.

GLP-1 Genetics & Diabetes Care: New research suggests about 10% of people carry genetic variants linked to “GLP-1 resistance,” meaning drugs like Ozempic may lower blood sugar less effectively for some patients—raising the case for more personalized obesity and diabetes treatment. Weight-Loss Drug Access: A once-daily Wegovy pill (semaglutide) is reported to be on track for UK approval “within days,” potentially widening access beyond injections, though NHS coverage may still depend on NICE. Rheumatology Support in Practice: At EULAR 2026, Danish-led work on combining tailored physical activity with cognitive behavioural approaches for inflammatory arthritis fatigue showed feasibility across Denmark and Sweden, with follow-up results hinting at reduced fatigue. EU Public Health Policy: Negotiations on tougher EU tobacco taxation rules have stalled after Sweden refused to back the proposal, putting a major public health initiative on hold. Child Online Safety & Regulation: Nigeria’s communications ministry survey found 83.4% support restricting children’s social media use, with many favoring outright regulation or parental controls. Denmark-Linked Health Tech: Denmark’s presidency push for tobacco hikes and broader EU health policy debates continue as member states resist unanimous decisions.

Denmark Water Policy: The Danish government confirms it will sharply lower the legal nitrate limit in drinking water to cut long-term cancer risk, with Greenpeace urging New Zealand to follow. Child Online Safety: Denmark is cited alongside France and Norway as part of a growing push for stricter age-based social media rules, as a new consultation in Guyana looks to draft protections for under-16s. Diabetes & Bone Health: A Danish registry study links both type 1 and type 2 diabetes to higher femoral and hip fracture risk, with type 1 remaining significant after age adjustment. Obesity Drugs & Access: Generic semaglutide is now available in Canada, raising questions about real-world pricing and availability; meanwhile, Novo Nordisk’s tablet “Wegovy pill” is reported to be moving toward UK approval. Healthcare Innovation: Microsoft and Mayo Clinic unveil a “safe and trusted” AI for healthcare, while Denmark-linked research highlights new pathways behind breast cancer dormancy in bone marrow. EU Health & Migration: EU countries race to set up “return hubs” abroad, with Denmark among a coalition exploring models and locations. Business & Wellness Distribution: Cosmos Health expands its Sky Premium Life nutraceutical brand across all 27 EU member states via Skroutz.

Diabetes & Bone Health: A Danish nationwide study links both type 1 and type 2 diabetes to higher rates of femoral and hip fractures in older adults, with type 1 diabetes still showing a significant site-specific risk after age adjustment. AI for Care: Microsoft and Mayo Clinic are building a “safe and trusted” AI model for healthcare, aiming to support earlier diagnosis and more personalised treatment planning using anonymised data. Ebola Response in Europe: EU and WHO are stepping up support for Ebola outbreaks in DR Congo and Uganda, including surveillance, infection control, community work, and an air bridge delivering emergency supplies. Breast Cancer Dormancy: New research highlights how Notch2 signalling helps dormant breast cancer cells survive in bone marrow, pointing to potential targeted therapies. Public Health Policy: Denmark is moving to cut nitrate limits in drinking water to reduce cancer risk, as pressure mounts over agricultural pollution. Migration & Visas: EU states, including Denmark, are pushing for tougher rules to deny Russian tourist visas amid rising Schengen visa numbers. Sports Meets Health: DR Congo’s World Cup warm-up vs Chile was cancelled in Spain over Ebola concerns, with the team seeking alternatives. Child Safety Online: Japan’s government panel proposes stronger age checks and limits on some social media features to protect minors’ physical and mental health.

AI for healthcare: Microsoft and Mayo Clinic unveiled a new “safe and trusted” AI model built from Mayo’s medical knowledge and anonymised patient data, aiming to support earlier diagnosis and more personalised treatment planning. Obesity care gap: Sweden’s first national obesity review warns that hundreds of thousands of people are undiagnosed or not getting effective treatment, with primary care flagged as a key bottleneck for earlier help. Bladder cancer screening trigger: A Danish study suggests starting aspirin (and to a lesser extent NSAIDs) is linked to more cystoscopies, potentially “unmasking” otherwise asymptomatic bladder cancer. Childhood vaccines politics: The US is reviewing childhood vaccine recommendations after a federal order, following earlier moves that cut the number of recommended vaccines. Denmark election resilience: Danish authorities say monitoring found no major foreign influence campaigns ahead of Denmark’s March 2026 election, including analysis focused on TikTok. Local wellness tourism: Cori Hornbæk Hotel in North Jutland will reopen as a year-round luxury wellness resort in August 2026 after major renovations.

Ebola & Public Health: DR Congo’s World Cup warm-up against Chile in Spain was cancelled after the mayor of La Línea de la Concepción cited Ebola-related health risks, with the team already disrupted by a cancelled training camp and now looking at options like playing behind closed doors. Cancer Screening Signals: A Danish study suggests aspirin use may “unmask” otherwise asymptomatic bladder cancer, with higher cystoscopy rates among aspirin starters prompting earlier detection. Diabetes & Pregnancy Risks: Denmark data links gestational diabetes to a much higher later risk of diabetic retinopathy, with risk rising alongside severity and post-pregnancy hypertension. Obesity Drug Access (EU): France set a firm reimbursement date for Wegovy and Mounjaro from June 15, making it the first EU country to refund obesity drugs under its health scheme. Denmark Water Policy: Denmark plans an EU-first cut to the nitrate limit in drinking water to reduce cancer risk, targeting pollution largely driven by intensive animal farming. Digital Safety & Kids: Denmark PM Mette Frederiksen reignited debate by comparing unsupervised social media use to smoking, as Europe considers tighter rules for children online. AI in Care: A report highlights how clinicians struggle to stay present with patients in fragmented care, while AI could help connect health issues—though many say they’re not trained to evaluate AI. Intimate Health Tech: Coloplast’s next-generation inflatable penile prosthesis (Titan Prime) won FDA approval, aiming to expand long-term treatment options for severe erectile dysfunction.

Ebola Watch (DR Congo): Spain’s La Línea mayor has cancelled a June 9 DR Congo–Chile pre-World Cup friendly after local health authorities flagged Ebola risks, with the team already shifting preparations to Belgium. Maternal Health: A Danish cohort study links preeclampsia with higher long-term hypertension and chronic kidney disease, with higher urinary protein excretion raising hypertension risk. Gut-to-Cancer Research: Danish and Australian scientists report a newly described virus carried by Bacteroides fragilis in colorectal cancer patients, helping explain a long-standing gut-bacteria paradox. Oral Health & Heart Risk: A large Denmark/UK analysis finds severe childhood cavities and high gingivitis scores are associated with higher adult cardiovascular disease incidence. Child Online Safety: Denmark is referenced in a wider push for stronger protections for children online, including stricter age checks and limits on features. Weight-Loss Drug Science: Coverage highlights orforglipron, an oral GLP-1 agonist candidate, as a major step beyond injectable options. Public Health & Climate: A new analysis warns the “safe window” for Hajj heat is shrinking as Mecca’s May temperatures rise with climate change. Policy & Care Access: A draft Danish coalition agreement signals free dental care and lower food VAT, alongside broader tax and defence commitments.

Maternal Health Research (Denmark): A Danish cohort study links preeclampsia plus higher urinary protein excretion to higher long-term risks of hypertension and chronic kidney disease, while not showing a clear link to cardiovascular disease. Cancer & Prevention: A new global analysis finds no “safe” level of alcohol—just one drink a day is tied to higher risk for multiple cancers. Cancer Care Backlog (COVID impact): Researchers estimate about 55,000 cancer diagnoses were “missing” across seven high-income countries during early pandemic disruption, including Denmark, highlighting lasting screening and diagnostic delays. Health Literacy (Pregnancy): A qualitative study explores how women seek and judge online pregnancy health information, pointing to gaps in maternal eHealth literacy. Policy & Access (Denmark): A draft coalition agreement signals major changes on food VAT and dental care, alongside tax reforms and higher defence spending. Metabolic Health (Industry): Zealand Pharma will take part in the Goldman Sachs Global Healthcare Conference, with CEO Adam Steensberg set for a fireside chat.

Legal Showdown in Weight-Loss Drugs: Novo Nordisk is taking South Africa compounding pharmacy iDexis to court over alleged knock-off semaglutide weight-loss jabs, with a Pretoria hearing set for June 10. Access Delays for Rare Diseases: Sweden’s wait for newly authorised orphan medicines has jumped to an average of 651 days, up sharply from last year, as patients and advocates push for faster availability. Migration Policy With Health Implications: The EU has agreed a tougher “return regulation” to speed deportations, including controversial “return hubs” outside the bloc—raising concerns for rights and public health planning. Online Safety for Teens: Malaysia starts enforcing a ban on social media accounts for under-16s, requiring age checks for major platforms and threatening large fines for non-compliance. Denmark Pharma Watch: Zealand Pharma reports transactions under its share buy-back program for week 22. Wellness in Copenhagen: A new Water Culture House is planned for Copenhagen Harbour, adding heated pools and wellness facilities to the city’s spa culture.

Ebola Watch (EU): EU health ministers are set to discuss coordinated action as Ebola spreads in the Democratic Republic of Congo, with Italy pushing for stricter border controls while the WHO warns against travel bans that could reduce transparent reporting. Humanitarian Response (Denmark-linked): UNICEF is airlifting urgent Ebola supplies from its Copenhagen hub to the DRC, including protective gear, medicines and hygiene kits, aiming to support nearly 100,000 people amid disrupted access to care. Obesity Drug (Denmark pharma): Novo Nordisk’s Wegovy oral weight-loss pill has been approved for use in the UAE, with pricing expected to start around Dh800–Dh1,600, adding to the growing shift from injections to tablets. Digital Health & IDs (Denmark): iDenfy expanded reusable digital identity verification by integrating Denmark’s MitID, aiming to reduce drop-offs in onboarding for services used across healthcare and banking. Metabolic Health (Zealand Pharma): Zealand Pharma reported transactions under its DKK 1.3bn share buy-back program for week 22 (May 26–29). Wellness Infrastructure (Copenhagen): Copenhagen Harbour is set to get a new Water Culture House bathhouse, adding heated pools and community wellness facilities. Early-Life Health: A study links early-life stress to higher long-term gastrointestinal disease risk, pointing to lasting changes in gut-nerve pathways. Public Health Policy (Malaysia): Malaysia began enforcing a ban on social media accounts for children under 16, requiring age verification and phased rollout for existing users. Sports Tragedy (Health & Safety): Greek defender Marios Oikonomou, 33, died nine days after a motorbike crash, underscoring the severe risks of road accidents.